Results 221 to 230 of about 111,189 (247)

Rituximab: an update

Lupus, 2007
openaire   +2 more sources

Rituximab

Reactions Weekly, 2020
openaire   +2 more sources

Rituximab

Reactions Weekly, 2014
openaire   +2 more sources

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Lancet, The, 2013
Dieter Hoelzer, Mathias J Rummel, Gerhard Heil   +2 more
exaly  

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Lancet, The, 2011
Isabelle D'Hondt, David Simpson, Rene-Olivier Casasnovas   +2 more
exaly  

Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review

Autoimmunity Reviews, 2018
Eric Hachulla, David Launay, Arsene Mékinian   +2 more
exaly  

Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab

European Journal of Nuclear Medicine and Molecular Imaging, 2015
Danielle Vugts, Dominique Bron, Patrick Flamen   +2 more
exaly  

Rituximab

Reactions Weekly, 2018
openaire   +2 more sources

Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL

Annals of Oncology, 2014
S Zeynalova, A Viardot, L Trumper
exaly  

Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease

Journal of Autoimmunity, 2015
Diankantha Kumararatne, Darren Roberts, Federico Alberici   +2 more
exaly